MaRS (Medical and Related Sciences Discovery District) today announced a big step toward its goal of establishing Toronto as a leading global centre of bioscience commerce, with the addition of Salt Lake City-based NPS Pharmaceuticals and Boston-based VIMAC Ventures as tenants. To date, almost 600,000 square feet of the 700,000 square feet available in Phase One of MaRS Centre has been leased to 12 organizations including CMDF (Canadian Medical Discoveries Fund), Heenan Blaikie LLP, Innovations Foundation (University of Toronto), MDS Inc. (MDS Sciex Division), RBC Technology Ventures Inc., RBC Financial Group, and the Blueprint Initiative. NPS and VIMAC, a venture capital firm active in biosciences, have selected MaRS as the ideal global destination to pursue research and commercial opportunities in the fast-emerging medical and related technology fields.
